Skip to content
A463Assembly2023-2024 SessionSame asS2677

Require Notice for Drug Denials

Official title

“Requires notice of adverse step therapy determinations”

Sponsor John T. McDonald IIIAD-108+7 co-sponsorsAffects Finance
Status
Signed by Governor
Impact
6/10
Moderate
Outcome
Signed into law

Bill progress

Signed into law

What's happening

This bill requires insurance and health plans to provide detailed written notice when denying step therapy override requests, including reasons, appeal instructions, and alternative options.

Why it matters

  1. Improves transparency and patient understanding. by requiring insurers to clearly explain the clinical reasons for denying a step therapy override, making it easier for patients and providers to understand the rationale behind the decision.

  2. Empowers patients and providers to challenge denials. by mandating that denial notices include step-by-step appeal instructions, which could increase the likelihood of successful appeals and ensure patients get timely access to necessary treatments.

  3. Promotes informed decision-making. by requiring information on alternative covered medications and the criteria used for denial, helping patients and doctors discuss and consider other available treatment options.

  4. Supports digital access and patient choice. by allowing required information to be delivered electronically—if the patient consents—potentially speeding up communication and reducing paperwork delays.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Require Notice for Drug Denials

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
John T. McDonald III

Assembly Member · Assembly District 108

Chair, Governmental Operations

History

  1. Approval memo.61
  2. Signed chap.735
  3. Delivered to governor
  4. Returned to assembly
  5. Passed senateVote 61–0
  6. 3rd reading cal.1179
  7. Substituted for S2677A
  8. Referred to rules
  9. Delivered to senate
  10. Passed assembly
  11. Ordered to third reading rules cal.483
  12. Rules report cal.483
Show 4 earlier actions
  1. Reported
  2. Amend and recommit to rules 463a
  3. Reported referred to rules
  4. Referred to insurance

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

S2677Senate

Notify Patients of Denied Treatments

Senate Floor Calendar · Sponsor Neil D. Breslin

Impact 6 · Moderate0% to pass

Full text

3 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

463--A

2023-2024 Regular Sessions

IN ASSEMBLY

January 9, 2023

Introduced by M. of A. McDONALD, STECK, GUNTHER, STIRPE, K. BROWN, WEPRIN, COLTON, BENDETT -- read once and referred to the Committee on Insurance -- reported and referred to the Committee on Rules -- Rules Committee discharged, bill amended, ordered reprinted as amended and recommitted to the Committee on Rules

AN ACT to amend the insurance law and the public health law, in relation to requiring notice of adverse step therapy determinations

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Subsection (a) of section 4902 of the insurance law is amended by adding a new paragraph 14 to read as follows:

(14) Establishment of a written procedure to assure that the notice of an adverse determination in relation to a step therapy protocol override determination request includes:

(i) the reasons for the determination including the clinical rationale, if any;

(ii) instructions on how to initiate standard and expedited appeals pursuant to section four thousand nine hundred four of this article and an external appeal pursuant to section four thousand nine hundred fourteen of this article;

(iii) information that includes: any applicable alternative covered medications; the clinical review criteria relied upon to make such determination; and any additional necessary information that must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal;

(iv) the provisions of this section shall be satisfied by making such information available electronically on a formulary website, on the member portal and/or provider portal of the insurer's, the health maintenance organization's website, or the website of an organization subject to article forty-three of this chapter, provided that the member consents to receiving the information electronically.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD02500-03-3

§ 2. Section 4903 of the insurance law is amended by adding a new subsection (e-1) to read as follows:

(e-1) Notice of an adverse determination made by a utilization review agent in relation to a step therapy protocol override determination request shall be made in writing to the insured or the insured's authorized representative and the insured's prescribing health care professional as defined in subsection (f) of section forty-nine hundred of this chapter, and shall include:

(i) the reasons for the determination including the clinical rationale, if any;

(ii) instructions on how to initiate standard and expedited appeals pursuant to section four thousand nine hundred four of this article and an external appeal pursuant to section four thousand nine hundred fourteen of this article;

(iii) information that includes: any applicable alternative covered medications; the clinical review criteria relied upon to make such determination; and any additional necessary information that must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal;

(iv) the provisions of this section shall be satisfied by making such information available electronically on a formulary website, on the member portal and/or provider portal of the insurer's, the health maintenance organization's website, or the website of an organization subject to article forty-three of this chapter, provided that the member consents to receiving the information electronically.

§ 3. Subdivision 1 of section 4902 of the public health law is amended by adding a new paragraph (l) to read as follows:

(l) Establishment of a written procedure to assure that the notice of an adverse determination in relation to a step therapy protocol override determination request includes: (i) the reasons for the determination including the clinical rationale, if any; (ii) instructions on how to initiate standard and expedited appeals pursuant to subdivision two of section forty-nine hundred four of this title and an external appeal pursuant to section forty-nine hundred fourteen of this article; (iii) information that includes: any applicable alternative covered medications; the clinical review criteria relied upon to make such determination; and any additional necessary information that must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal; (iv) the provisions of this section shall be satisfied by making such information available electronically on a formulary website, on the member portal and/or provider portal of the insurer's, the health maintenance organization's website, or the website of an organization subject to article forty-three of this chapter, provided that the member consents to receiving the information electronically.

§ 4. Section 4903 of the public health law is amended by adding a new subdivision 5-a to read as follows:

5-a. Notice of an adverse determination made by a utilization review agent in relation to a step therapy protocol override determination request shall be made in writing to the enrollee or the enrollee's authorized representative and the enrollee's prescribing health care professional as defined in subdivision six of section forty-nine hundred of this title, and shall include:

(a) the reasons for the determination including the clinical rationale, if any;

(b) instructions on how to initiate standard and expedited appeals pursuant to section forty-nine hundred four of this title and an external appeal pursuant to section forty-nine hundred fourteen of this article;

(c) information that includes: any applicable alternative covered medications; the clinical review criteria relied upon to make such determination; and any additional necessary information that must be provided to, or obtained by, the utilization review agent in order to render a decision on the appeal;

(d) the provisions of this section shall be satisfied by making such information available electronically on a formulary website, on the member portal and/or provider portal of the insurer's, the health maintenance organization's website, or the website of an organization subject to article forty-three of this chapter, provided that the member consents to receiving the information electronically.

§ 5. This act shall take effect on the ninetieth day after it shall have become a law. Effective immediately, the addition, amendment and/or repeal of any rule or regulation necessary for the implementation of this act on its effective date are authorized to be made and completed on or before such effective date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.